Format

Send to

Choose Destination
Nat Prod Res. 2018 Nov 8:1-9. doi: 10.1080/14786419.2018.1495639. [Epub ahead of print]

Excelsanone, a new isoflavonoid from Erythrina excelsa (Fabaceae), with in vitro antioxidant and in vitro cytotoxic effects on prostate cancer cells lines.

Author information

1
a Centre for Research on Medicinal Plants and Traditional Medicine , Institute of Medical Research and Medicinal Plants Studies , Yaounde , Cameroon.
2
b Department of Organic Chemistry, Faculty of Sciences , University of Yaounde 1 , Yaounde , Cameroon.
3
c Department of Life and Earth Sciences , Higher Teachers' Training College, University of Maroua , Maroua , Cameroon.
4
d Department of Chemistry, Faculty of Sciences , University of Ngaoundere , Ngaoundere , Cameroon.
5
e Laboratory of Pharmacognosy, Department of Pharmacy , CIRM, University of Liege , Liege , Belgium.

Abstract

A new isoflavonoid, excelsanone (2), was isolated from the ethyl acetate extract of Erythrina excelsa stem bark, together with three known compounds namely 6,8-diprenylgenistein (3), β-sitosterol (1) and sitosteryl-β-D-glucopyranoside (4). Their structures were elucidated using spectroscopic methods (HR-ESI-MS, NMR and IR) and by comparison with some literature data. The antioxidant activity of crude extracts and two isolated compounds was evaluated using free radical scavenging (DPPH) and Ferric Reducing Ability Power (FRAP) methods with catechin as standard. The results of the radical scavenging activity showed that excelsanone (2) has a moderate potential with an IC50 of 1.31 mg/ml. The cytotoxicity of compounds 2 and 3 as well as the ethyl acetate extract was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in two prostate cancer cell lines (DU145 and PC3). Excelsanone (2) induced a greater cytotoxicity in all tested cell lines, with a significant inhibition of DU145 cells growth in a concentration-dependent manner.

KEYWORDS:

Erythrina excelsa; Fabaceae; antioxidant; cytotoxicity; isoflavonoid

Supplemental Content

Loading ...
Support Center